Life-saving medicines missing on the German Market as of 12.09.2024. “The current legislation has no effect whatsoever,” says Mr. Holger Seyfarth, the Chairman of the HAV (Hessian Pharmacists’ Association), urgently calling for reforms to combat the ongoing supply bottlenecks and an immediate improvement in the supply of medicines.
Although more than a year has passed since the law against supply bottlenecks (ALBVVG) came into force, approximately. 500 medicines are still in short supply, including different antibiotics (amoxicillin, doxycycline, etc.), insulin, and cancer drugs. The measures taken aren’t sufficient and in an official letter to the Federal Ministry of Health (BMG), the HAV calls for an immediate end to the price dictation of the health insurance companies for discount contracts, more transparency in the supply chains, and a new regulation of the strategic stockpiling of essential medicines in local pharmacies – including financial support.
According to Seyfarth, the results are so unsatisfying that urgent changes are needed in several aspects, for example, to decrease the bureaucratic hurdles and provide more incentives for the pharmaceutical companies to create additional production capacities in Europe. The dependence on Asian manufacturers has already shown how critical the situation could be during pandemic waves or even flu epidemics.
“It is completely unacceptable that people in Germany cannot be supplied with the necessary medicines. Here, politicians have a duty to take appropriate measures immediately to remedy this situation,” Seyfarth emphasizes.
Source: Supply bottlenecks: HAV demands stockpiling fee | PHARMACY ADHOC (apotheke-adhoc.de)
Disclaimer:
As a service to our readers, MVS Pharma GmbH publishing provides access to our library of archived content in our blog. Please note the date of the last review or update on all articles. No content on this site should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
MVS Pharma GmbH will soon be launching the MVS Omega-3 medical-grade supplement onto the European market, which has been developed for the highest quality standards in terms of oxidation avoidance and, therefore greatest bioavailability. In addition, in vitro studies are currently underway at the University of Ulm, in which Professor Dr. Rüdiger Groß tested a patented mouth and nose spray (Virudol) that can eliminate various flu viruses based on natural substances.
In addition, MVS has a wholesale license and has specialized in sourcing much-needed medicines such as Amoxicillin, Salbutamol, etc. from India through its local branch with a focus on local quality and safety testing, compliance with international GMP regulations and the highest quality level of user security (examples of local language brochures, identical units of measurement, batch control and full tracking, etc.).
